Holistic Planning LLC Sells 4,750 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Holistic Planning LLC cut its position in Nkarta, Inc. (NASDAQ:NKTX) by 31.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,450 shares of the company’s stock after selling 4,750 shares during the quarter. Holistic Planning LLC’s holdings in Nkarta were worth $47,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of Nkarta by 110.9% during the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock worth $45,000 after purchasing an additional 5,243 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Nkarta in the third quarter valued at approximately $93,000. Forefront Analytics LLC acquired a new stake in Nkarta during the second quarter worth approximately $70,000. The Manufacturers Life Insurance Company increased its stake in Nkarta by 92.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,710 shares of the company’s stock worth $122,000 after acquiring an additional 9,975 shares during the period. Finally, AQR Capital Management LLC acquired a new position in Nkarta in the 2nd quarter valued at $938,000. 80.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Raymond James upgraded Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 price target on the stock in a research report on Wednesday, August 14th. Needham & Company LLC decreased their target price on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Friday. Rodman & Renshaw started coverage on shares of Nkarta in a report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target for the company. RODMAN&RENSHAW raised shares of Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Finally, HC Wainwright cut their target price on Nkarta from $23.00 to $22.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $17.17.

Nkarta Price Performance

Shares of NASDAQ:NKTX opened at $3.19 on Friday. The firm has a 50 day simple moving average of $4.39 and a 200 day simple moving average of $5.56. The company has a market cap of $225.09 million, a price-to-earnings ratio of -1.59 and a beta of 0.86. Nkarta, Inc. has a one year low of $1.90 and a one year high of $16.24.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.15. As a group, analysts expect that Nkarta, Inc. will post -1.92 EPS for the current year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.